92562-88-4

92562-88-4 structure

Name: Lagociclovir
Chemical Name: 2-amino-9-[(2R,4S,5R)-4-fluoro-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one
CAS Number: 92562-88-4
Molecular Formula: C₁₀H₁₂FN₅O₃
Molecular Weight: 269.232
Catalog: Signaling Pathways Anti-infection HBV
Create Date: 2018-06-21 17:38:40
Modify Date: 2024-01-10 10:22:10
Lagociclovir(MIV-210) is a prodrug of 3'-fluoro-2',3'-dideoxyguanosine with high oral bioavailability in humans and potent activity against HBV. IC50 value:Target: Anti-HBV compoundOral administration of MIV-210 at 20 or 60 mg/kg of body weight/day induced a rapid virological response in chronically infected woodchucks, reducing serum WHV DNA levels by 4.75 log10 and 5.72 log10, respectively, in 2 weeks. Further, a daily dose of 10 mg/kg decreased the serum WHV load 400-fold after 4 weeks of treatment, and a dose of 5 mg/kg/day was sufficient to maintain this antiviral effect during the following 6-week period. MIV-210 at 20 or 60 mg/kg/day reduced the liver WHV DNA load 200- to 2,500-fold from pretreatment levels and, importantly, led to a 2.0 log10 drop in the hepatic content of WHV covalently closed circular DNA.

Name	2-amino-9-[(2R,4S,5R)-4-fluoro-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one
Synonyms	Guanosine, 2',3'-dideoxy-3'-fluoro- UNII-UU109JJU0U Guanosine,2',3'-dideoxy-3'-fluoro Fddguo 3'-fluoro-2',3'-dideoxyguanosine 2',3'-Dideoxy-3'-fluoroguanosine Lagociclovir 3'-fluoro-3'-deoxyguanosine 3'-FddG

Description	Lagociclovir(MIV-210) is a prodrug of 3'-fluoro-2',3'-dideoxyguanosine with high oral bioavailability in humans and potent activity against HBV. IC50 value:Target: Anti-HBV compoundOral administration of MIV-210 at 20 or 60 mg/kg of body weight/day induced a rapid virological response in chronically infected woodchucks, reducing serum WHV DNA levels by 4.75 log10 and 5.72 log10, respectively, in 2 weeks. Further, a daily dose of 10 mg/kg decreased the serum WHV load 400-fold after 4 weeks of treatment, and a dose of 5 mg/kg/day was sufficient to maintain this antiviral effect during the following 6-week period. MIV-210 at 20 or 60 mg/kg/day reduced the liver WHV DNA load 200- to 2,500-fold from pretreatment levels and, importantly, led to a 2.0 log10 drop in the hepatic content of WHV covalently closed circular DNA.
Related Catalog	Signaling Pathways >> Anti-infection >> HBV Research Areas >> Infection
References	[1]. Michalak TI, et al. Profound antiviral effect of oral administration of MIV-210 on chronic hepadnaviral infection in a woodchuck model of hepatitis B. Antimicrob Agents Chemother. 2009 Sep;53(9):3803-14.